$330 Million is the total value of CHI Advisors LLC's 26 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VECT | Sell | VECTIVBIO HLDG AG | $46,945,093 | +5.0% | 2,782,756 | -47.1% | 14.24% | +20.0% |
| Sell | 2SEVENTY BIO INC | $8,622,311 | -1.1% | 852,007 | -0.4% | 2.62% | +13.0% | |
| INZY | Sell | INOZYME PHARMA INC | $6,656,301 | -13.5% | 1,195,027 | -11.0% | 2.02% | -1.1% |
| Sell | ORCHARD THERAPEUTICS PLCspon ads new | $3,937,394 | -6.7% | 755,738 | -3.8% | 1.20% | +6.7% | |
| Sell | RALLYBIO CORP | $3,072,101 | -29.3% | 542,774 | -28.6% | 0.93% | -19.2% | |
| DTIL | Sell | PRECISION BIOSCIENCES INC | $843,471 | -67.7% | 1,603,557 | -53.8% | 0.26% | -63.1% |
| CRVS | Sell | CORVUS PHARMACEUTICALS INC | $458,000 | -78.5% | 200,000 | -91.5% | 0.14% | -75.4% |
| RXDX | Exit | PROMETHEUS BIOSCIENCES INCcall | $0 | – | -25,000 | -100.0% | -0.03% | – |
| ONCR | Exit | ONCORUS INC | $0 | – | -2,367,436 | -100.0% | -0.22% | – |
| Exit | ENTRADA THERAPEUTICS INC | $0 | – | -56,374 | -100.0% | -0.22% | – | |
| FRLN | Exit | FREELINE THERAPEUTICS HLDGSsponsored ads | $0 | – | -4,729,419 | -100.0% | -0.57% | – |
| KZR | Exit | KEZAR LIFE SCIENCES INC | $0 | – | -689,451 | -100.0% | -0.57% | – |
| KDNY | Exit | CHINOOK THERAPEUTICS INC | $0 | – | -135,000 | -100.0% | -0.83% | – |
| RXDX | Exit | PROMETHEUS BIOSCIENCES INC | $0 | – | -934,135 | -100.0% | -26.61% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-08-22
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.